# A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection

> **NCT02421211** · PHASE2 · COMPLETED · sponsor: **Janssen Sciences Ireland UC** · enrollment: 41 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Simeprevir (SMV)
- **DRUG:** Ledipasvir (LDV)
- **DRUG:** Sofosbuvir (SOF)

## Key facts

- **NCT ID:** NCT02421211
- **Lead sponsor:** Janssen Sciences Ireland UC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-19
- **Primary completion:** 2015-11-10
- **Final completion:** 2016-01-27
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2019-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02421211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02421211, "A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02421211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*